EIM Group
http://www.eimgroup.com/jahia/page2.htmlEIM Group is a fund of fund that focuses on identifying, screening, and analyzing the best fund managers in different markets and investment styles.
View Older Stories View More Recent Stories
-
GE Healthcare (GE) Commences Flutemetamol Phase 3, To Present Phase 2 Data at HAI Meeting in Toronto
-
Analysts Mixed On Forest Labs (FRX) After Daxas Fail
-
Star Scientific (CIGX) Sees Morning Upside Following Analyst Highlight of Possible Alzheimer Cure
-
Ardea Biosciences (RDEA) to Offer 3.5M in Common Stock
-
Goldman Sachs (GS) Set Up For Another Earnings 'Beat', But Does It Matter?
-
Boeing (BA) to Recognize $150M, 20c/Share Income Tax Charge from Healthcare Bill
-
Daily State of the Markets 3/29: That Sinking Feeling
-
Lions Gate (LGF) Tells Icahn to Get Lost
-
Lionsgate (LGF) Calls Carl Icahn Offer "Inadequate and Coercive"
-
athenahealth (ATHN): Priced for Perfection, But Is Perfection Moving Out of Reach? Downgrade to Underperform - Oppenheimer
-
Notable Analyst Rating Changes 03/17: BLK, LNC, ADBE, GE Upgraded; FUQI, NUE, CTXS, ERIC Downgraded
-
Sensata Technologies (ST) IPO Trades Slightly Higher
-
Abbott (ABT) Agrees to Buy Facet Biotech (FACT) for $27/Share in Cash
-
Daily State of the Markets 3/9: Happy Birthday!
-
Top 10 News Items 3/1-3/5: Nonfarm Payrolls Better-Than-Expected, Greece Sells Debt in the Open Market, Ford Surpasses GM as Top US Autoseller
-
Medivation (MDVN) Plunges 70% After Alzheimer Drug Fails In Late Trials
-
Crude Carriers (CRU) Files 13.5M Share IPO; Sees Price of $19-$21
-
Needham & Company Upgrades NuVasive (NUVA) to Strong Buy
-
Corning (GLW): When Things Are Too Good to Last, They Don't - Oppenheimer
-
Oppenheimer Downgrades Corning (GLW) to Perform
-
CEL-SCI (CVM) Surging on Update for Multikine Cancer Drug and H1N1 Treatment
-
Notable Analyst Rating Changes 02/17: SNDK, HD, WFMI, ABFS Upgraded; VCLK, SNI, PAAS, CHE Downgraded
-
Oppenheimer Starts Mylan (MYL), Warner Chilcott (WCRX) at Outperform
-
Merriman Curhan Ford Initiates Coverage on Avanir Pharmaceuticals (AVNR) with a Buy; Compelling Small-Cap
-
Oppenheimer Lifts Price Target On General Electric (GE) to $20
-
Century 21 China (CTC) IPO Trades Slightly Higher
-
IPO of Century 21 China (CTC) Prices at $7, Bottom End of Lowered Range
-
Amazon.com (AMZN): Oppenheimer Makes a Call to Buy the Stock Ahead of Q4 Results
-
Analyst Thoughts On General Electric (GE) Following Q4 Results
-
Apple (AAPL) Q1 Earnings Preview
-
JPMorgan (JPM) Shares Upgraded Intraday at Oppenheimer
-
Obama Confirms TARP Tax
-
Coffee, The New Miracle Drug
-
Highlights From WAG's Q1 Conference Call: Sales Were $16.4 Billion, Up 9.5% Y-O-Y
-
Notable Analyst Rating Changes 12/16: CNQ, SCHW, RCL, CCL, NLY, GLW, BFS, ADBE Upgraded; AYE, FE, EIX, STLD Downgraded
-
Is Glass-Steagall Coming Back?
-
Evergreen Energy (EEE) and Enterprise Info Management Collaborate On 2010 CHG Marketing Campaign
-
Best Buy (BBY) Looks To Give Investors an Early Christmas Gift
-
Apple (AAPL) Preparing For March or April Tablet Launch - Analyst
-
Notable Analyst Rating Changes 12/07: POT, BRCD, SPWRA, STP, JASO, AXP Upgraded; MMC, ABX, ALTH, AVP, ZLC Downgraded
-
CF Industries (CF) Boosts Offer for Terra (TRA) by $4.75/Share in Cash
-
Oppenheimer Starts Visa (V) and MasterCard (MA) at Outperform
-
UnitedHealth (UNH) Granted Preliminary Approval in $350M Class Action Lawsuit
-
'Cash for Clunkers' 3-Months Later: A Boon or a Bust?
-
Wedbush Maintains a 'Neutral' on Endo Pharmaceuticals (ENDP); Adjusts Estimates & PT Ahead of Anticipated Aveed Approval
-
Federal Signal (FSS) Comments on Hearing Loss Litigation
-
Notable Analyst Rating Changes 11/24: ABG, PRU, RS, AYI, AMLN, TLAB Upgraded; DELL, CIEN, UNP, ALV Downgraded
-
Microvision (MVIS) Prices 6.7M Common Offering at $3/Share
-
Traders Applaud Oppenheimer's Upgrade of GSI Commerce (GSIC)
-
Lazard (LAZ) Jumps Higher Amid Intraday Oppenheimer Upgrade

